Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations
In this cohort study of 22 576 individuals with chronic HCV infection, successful HCV treatment with DAAs was associated with lower risk of several EHMs. These findings highlight the importance of early HCV screening and treatment to prevent EHMs and improve overall health outcomes.
Authors
- Prince Adu (ORCID: https://orcid.org/0000-0002-3983-0875)
- Amee R. Manges (ORCID: https://orcid.org/0000-0003-2462-7249)
- Jean Damascène Makuza (ORCID: https://orcid.org/0000-0001-9275-8844)
- Dahn Jeong (ORCID: https://orcid.org/0000-0003-1782-5669)
- Héctor Alexander Velásquez García (ORCID: https://orcid.org/0000-0002-0764-4664)
- Mohammad Ehsanul Karim (ORCID: https://orcid.org/0000-0002-0346-2871)
- Naveed Zafar Janjua (ORCID: https://orcid.org/0000-0001-5681-719X)
- Sofia Bartlett (ORCID: https://orcid.org/0000-0003-0699-2250)
- Mawuena Binka (ORCID: https://orcid.org/0000-0002-9370-1708)
- Mel Krajden (ORCID: https://orcid.org/0000-0002-3477-8748)
- Stanley Wong (ORCID: https://orcid.org/0000-0003-0886-9889)
- Amanda Yu
Institutions
- University of British Columbia (CA)
- St. Paul's Hospital (CA)
- BC Centre for Disease Control (CA)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.14631
- Citations
- 4
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 5.29
Funders
- AstraZeneca
- Gilead Sciences
- Public Health Agency of Canada
- Public Health Agency
- Provincial Health Services Authority
- British Columbia Centre for Disease Control
- Canadian Institutes of Health Research